Non-Hodgkin lymphoma Posts on Medivizor
Navigation Menu

Non-Hodgkin lymphoma Posts on Medivizor

Evaluating SCR chemotherapy for patients with non-Hodgkin’s lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness and safety of a new chemotherapy regimen for patients with non-Hodgkin’s lymphoma (NHL). This study concluded that this regimen was highly effective for these patients, but was associated with some side effects. Some background For patients with NHL, age is one determining factor for treatment...

Read More

Using liver AST levels to predict outcomes for patients with diffuse large B-cell lymphoma

Posted by on Jun 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study examined the impact of aspartic transaminase (AST) levels in the blood on survival outcomes for patients with diffuse large B-cell lymphoma (DLBCL). This study concluded that high levels of AST in the blood were associated with poorer treatment outcomes for these patients. Some background DLBCL is one of the most common types...

Read More

Nanodrugs

Nanodrugs

Posted by on Jun 29, 2019 in Blog, Breast cancer, Colorectal cancer, Lung cancer, Lymphoma, Melanoma, Multiple Myeloma, Non-Hodgkin lymphoma, Parkinson's Disease, Prostate cancer | 0 comments

Nanodrugs have been around for some time. In fact, over 250 drugs using nanotechnology that  have been approved by the FDA and are in clinical use. The name nanodrug or nanopharmaceuticals refers to the size of the particle that is created to house the medication. A nano is very tiny: nanoparticles are between 1 and 100 nanometers in at least one of its...

Read More

Searching for patients with unresponsive cancer to test a new treatment

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1/2 trial will investigate the safety of 9-ING-41, for treatment-resistant cancers.  The main outcome will be the number of treatment-related adverse events (TRAEs). This trial is recruiting in the United States. The details Some cancers may not respond to conventional treatment. Treatment-resistant cancers are called...

Read More

Searching for patients with recurrent or non-responsive lymphoma to try this new treatment option

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 1 study is evaluating the safety and effectiveness of a new T-cell therapy combined with nivolumab (Opdivo) for patients with lymphoma that has come back or stopped responding to treatment. The main outcome to be measured will be the number of patients who have side effects. This study is recruiting in Washington, D.C. and Salt...

Read More

Searching for patients with untreated small lymphocytic lymphoma to test combined immunotherapy

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This phase 2 study is evaluating the effectiveness of a new combination therapy for small lymphocytic lymphoma (SLL). The main outcome to be measured will be the number of patients who have a complete disappearance of all signs of cancer. This study is recruiting in Rochester, New York, US. The details Typical treatments for SLL include...

Read More

Searching for participants with leukemia and lymphoma to try a new treatment before stem cell transplantation

Posted by on Jun 29, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study will investigate the effects of high-pressure oxygen on the transplant of umbilical cord blood stem cells in patients with blood cancers. The main outcome that will be measured is the time it takes for white blood cells to recover after treatment. This trial is recruiting in New York, US. The details Stem cell transplant (SCT)...

Read More

Searching for patients with relapsed or unresponsive non-Hodgkin lymphoma to try a new cell therapy

Posted by on Jun 24, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This Phase 2 study is evaluating the safety and effectiveness of a new T-cell therapy for B-cell non-Hodgkin’s lymphoma (NHL) that has come back or stopped responding to treatment. The main outcomes to be measured will be the number of patients who experience side effects and overall response after treatment. This trial is recruiting...

Read More

Managing side effects of ibrutinib treatment

Posted by on Jun 23, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study summarised the side effects of ibrutinib (Imbruvica) and how to manage them.  Some background Ibrutinib is an FDA approved drug used to treat lymphoma and leukemia. It works on the immune cells in the body which may lead to many side effects. These include diarrhea, upper respiratory infections, bleeding, tiredness, and...

Read More

Evaluating RBD chemotherapy for recurrent or non-responsive non-Hodgkin lymphoma

Posted by on Jun 21, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated how safe and effective RBD (rituximab, bendamustine, and dexamethasone) chemotherapy was for patients with B-cell non-Hodgkin lymphoma (NHL). This study concluded that this new regimen showed promising effectiveness for these patients. Some background Chemoimmunotherapy remains the standard first-line treatment...

Read More